Skip to main content

Caldwell Sutter Capital, Inc.

Source: SEC Form 13F · as of Mar 2026

Caldwell Sutter Capital, Inc. holds 48 biotech & pharma companies tracked by BioSniper, totaling $9.7M in value as of Mar 2026 (SEC Form 13F).

Companies held

48

Total value held

$9.7M

BioSniper AIPage evidence connected

Prepared research question

What matters most for PFIZER INC (PFE)—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

CompanySharesValue
PFEPFIZER INC66,343$1.9M
JNJJOHNSON & JOHNSON6,405$1.6M
MRKMerck & Co., Inc.9,394$1.1M
ABBVAbbVie Inc.5,123$1.1M
GILDGILEAD SCIENCES, INC.7,590$1.1M
PMPhilip Morris International Inc3,593$594K
AMGNAMGEN INC1,679$591K
BMYBRISTOL MYERS SQUIBB CO7,029$426K
ABTABBOTT LABORATORIES3,523$362K
UNHUnitedHealth Group Incorporated Common Stock (DE)1,143$309K
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)3,557$196K
BBIOBridgeBio Pharma, Inc.2,000$149K
GMOptec International, Inc.983$73K
VTRSViatris Inc3,187$43K
LLYELI LILLY & Co42$39K
PCVXVaxcyte, Inc.432$25K
ELANElanco Animal Health Inc892$21K
HALOHALOZYME THERAPEUTICS, INC.300$19K
GEHCGE HealthCare Technologies Inc.258$18K
SUNSUNSET ISLAND GROUP281$18K
NVONovo Nordisk A/S407$15K
MCKMcKesson Corporation15$13K
CORCencora Inc.32$10K
VRTXVERTEX PHARMACEUTICALS INC / MA21$9K
AZNASTRAZENECA PLC46$9K
FOLDAMICUS THERAPEUTICS, INC.400$6K
PRVBPROVENTION BIO, INC.500$6K
BIIBBIOGEN INC.30$6K
ZTSZoetis Inc.44$5K
LPCNLipocine Inc.471$4K
PRLDPrelude Therapeutics Inc1,000$3K
ATAIAtai Beckley N.V.700$2K
SNYSanofi50$2K
ELVElevance Health Inc.7$2K
IQVIQVIA Holdings Inc.12$2K
OGNOrganon & Co.300$2K
ZBHZimmer Biomet Holdings Inc.18$2K
CELUCelularity Inc.1,000$1K
ICLRICON plc12$1K
ACHAccendra Health Inc.400$912
SPRBSPRUCE BIOSCIENCES, INC.13$850
AUTLAutolus Therapeutics plc500$690
CGCCanopy Growth Corp624$592
SLSSELLAS Life Sciences Group, Inc.100$423
NVAXNOVAVAX INC50$407
ATYRaTYR PHARMA INC52$41
DAREDare Bioscience, Inc.17$31
IMUXIMMUNIC, INC.3$3

13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.